Payment overview · 2025
General Payments
$919.08
36 reported records · 13 companies
Healthcare provider profile · identity verified
Sherma Peter, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · SYLVANIA, GA · NPI 1518127687
Verified facts
What the public records show
CMS Open Payments records show Sherma Peter, M.D. received $919.08 in general payments during 2025 across 36 reported records.
AstraZeneca Pharmaceuticals LP accounted for 30.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Prolia, Rexulti, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 167 claims for Linzess by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 146 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 187 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 307 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $277.81 | 30.2% | 7 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $209.20 | 22.8% | 12 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $135.00 | 14.7% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $66.67 | 7.2% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $53.62 | 5.8% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $46.46 | 5.1% | 3 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $22.25 | 2.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $20.18 | 2.2% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $19.26 | 2.1% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $18.68 | 2.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.17 | 2.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.20 | 1.8% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.58 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $919.08 | 36 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $258.68 | 6 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $141.51 | 7 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $141.51 | 7 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $135.00 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $81.89 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $67.69 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $66.67 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $53.62 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $46.46 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $36.26 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $22.53 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $22.25 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $22.25 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $20.18 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $19.26 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $18.68 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $18.17 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.20 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $15.58 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 121 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 307 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 27 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 109 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
167 | 40 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
27 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
121 | 18 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
90 | 90 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
127 | 108 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
109 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
146 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
187 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
307 | 51 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 946 | 254 |
| Atorvastatin Calcium | Atorvastatin Calcium | 858 | 243 |
| Levothyroxine Sodium | Levothyroxine Sodium | 536 | 130 |
| Potassium Chloride | Potassium Chloride | 510 | 132 |
| Lisinopril | Lisinopril | 507 | 120 |
| Carvedilol | Carvedilol | 465 | 113 |
| Furosemide | Furosemide | 452 | 122 |
| Omeprazole | Omeprazole | 438 | 135 |
| Losartan Potassium | Losartan Potassium | 415 | 110 |
| Gabapentin | Gabapentin | 402 | 103 |
| Eliquis | Apixaban | 319 | 52 |
| Ozempic | Semaglutide | 307 | 51 |
| Pravastatin Sodium | Pravastatin Sodium | 294 | 75 |
| Famotidine | Famotidine | 284 | 73 |
| Tramadol Hcl | Tramadol Hcl | 280 | 83 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 271 | 76 |
| Metoprolol Succinate | Metoprolol Succinate | 270 | 66 |
| Pantoprazole Sodium | Pantoprazole Sodium | 258 | 72 |
| Metformin Hcl | Metformin Hcl | 237 | 57 |
| Metformin Hcl Er | Metformin Hcl | 234 | 64 |
| Clopidogrel | Clopidogrel Bisulfate | 216 | 56 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 215 | 60 |
| Simvastatin | Simvastatin | 214 | 45 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 211 | 69 |
| Alprazolam | Alprazolam | 211 | 53 |
| Sertraline Hcl | Sertraline Hcl | 206 | 57 |
| Tamsulosin Hcl | Tamsulosin Hcl | 206 | 59 |
| Trazodone Hcl | Trazodone Hcl | 202 | 54 |
| Hydrochlorothiazide | Hydrochlorothiazide | 196 | 55 |
| Allopurinol | Allopurinol | 191 | 51 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 190 | 59 |
| Mounjaro | Tirzepatide | 187 | 28 |
| Prednisone | Prednisone | 175 | 100 |
| Linzess | Linaclotide | 167 | 40 |
| Doxazosin Mesylate | Doxazosin Mesylate | 151 | 34 |
| Fluticasone Propionate | Fluticasone Propionate | 150 | 68 |
| Memantine Hcl | Memantine Hcl | 149 | 32 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 146 | 65 |
| Jardiance | Empagliflozin | 146 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 144 | 35 |
| Escitalopram Oxalate | Escitalopram Oxalate | 139 | 30 |
| Montelukast Sodium | Montelukast Sodium | 134 | 39 |
| Tizanidine Hcl | Tizanidine Hcl | 133 | 48 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 132 | 36 |
| Glimepiride | Glimepiride | 127 | 30 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 127 | 108 |
| Celecoxib | Celecoxib | 122 | 43 |
| Farxiga | Dapagliflozin Propanediol | 121 | 18 |
| Donepezil Hcl | Donepezil Hcl | 117 | 27 |
| Meclizine Hcl | Meclizine Hcl | 117 | 43 |
| Quetiapine Fumarate | Quetiapine Fumarate | 115 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 112 | 20 |
| Glipizide Er | Glipizide | 110 | 29 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 109 | 23 |
| Myrbetriq | Mirabegron | 107 | 17 |
| Pregabalin | Pregabalin | 106 | 29 |
| Pioglitazone Hcl | Pioglitazone Hcl | 104 | 31 |
| Zolpidem Tartrate | Zolpidem Tartrate | 104 | 25 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 99 | 57 |
| Atenolol | Atenolol | 93 | 24 |
| Spironolactone | Spironolactone | 92 | 28 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 91 | 29 |
| Ropinirole Hcl | Ropinirole Hcl | 91 | 23 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 90 | 90 |
| Tradjenta | Linagliptin | 89 | 11 |
| Levetiracetam | Levetiracetam | 88 | 16 |
| Cephalexin | Cephalexin | 86 | 55 |
| Duloxetine Hcl | Duloxetine Hcl | 84 | 23 |
| Januvia | Sitagliptin Phosphate | 81 | 13 |
| Finasteride | Finasteride | 78 | 24 |
| Hydralazine Hcl | Hydralazine Hcl | 77 | 18 |
| Amoxicillin | Amoxicillin | 74 | 63 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 74 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 73 | 25 |
| Repatha Sureclick | Evolocumab | 72 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 71 | 26 |
| Clonazepam | Clonazepam | 70 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 70 | 15 |
| Mirtazapine | Mirtazapine | 70 | 15 |
| Lorazepam | Lorazepam | 69 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 68 | 21 |
| Aripiprazole | Aripiprazole | 67 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 66 | 19 |
| Ezetimibe | Ezetimibe | 64 | 17 |
| Lovastatin | Lovastatin | 64 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 61 | 47 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 61 | 17 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 61 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 60 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 59 | 20 |
| Doxycycline Hyclate | Doxycycline Hyclate | 57 | 50 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 57 | 17 |
| Azithromycin | Azithromycin | 56 | 49 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 54 | 11 |
| Ketoconazole | Ketoconazole | 52 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 50 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 49 | 13 |
| Baclofen | Baclofen | 49 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 49 | 14 |
| Latanoprost | Latanoprost | 48 | suppressed |
| Meloxicam | Meloxicam | 48 | 25 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 47 | suppressed |
| Fluconazole | Fluconazole | 47 | 32 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 46 | 19 |
| Amiodarone Hcl | Amiodarone Hcl | 46 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 46 | 12 |
| Enalapril Maleate | Enalapril Maleate | 46 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 46 | 15 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 46 | 31 |
| Warfarin Sodium | Warfarin Sodium | 46 | suppressed |
| Xarelto | Rivaroxaban | 46 | suppressed |
| Nifedipine Er | Nifedipine | 44 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 43 | suppressed |
| Colchicine | Colchicine | 42 | 25 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 41 | suppressed |
| Bupropion Xl | Bupropion Hcl | 41 | 11 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 41 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 41 | 14 |
| Midodrine Hcl | Midodrine Hcl | 40 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 39 | 35 |
| Ibuprofen | Ibuprofen | 39 | 14 |
| Sevelamer Carbonate | Sevelamer Carbonate | 39 | suppressed |
| Valsartan | Valsartan | 39 | 11 |
| Calcitriol | Calcitriol | 38 | suppressed |
| Primidone | Primidone | 38 | suppressed |
| Trulicity | Dulaglutide | 38 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 37 | 12 |
| Entresto | Sacubitril/Valsartan | 37 | suppressed |
| Novolog Flexpen | Insulin Aspart | 37 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 35 | suppressed |
| Cefdinir | Cefdinir | 35 | 31 |
| Metolazone | Metolazone | 35 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 35 | suppressed |
| Methocarbamol | Methocarbamol | 34 | suppressed |
| Rexulti | Brexpiprazole | 34 | suppressed |
| Diazepam | Diazepam | 32 | suppressed |
| Estradiol | Estradiol | 32 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 31 | 15 |
| Kerendia | Finerenone | 31 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 31 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 30 | 14 |
| Divalproex Sodium | Divalproex Sodium | 30 | suppressed |
| Nystatin | Nystatin | 30 | 17 |
| Glipizide | Glipizide | 29 | 12 |
| Levofloxacin | Levofloxacin | 29 | 24 |
| Mupirocin | Mupirocin | 29 | 20 |
| Ondansetron Odt | Ondansetron | 29 | 16 |
| Rybelsus | Semaglutide | 29 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 28 | 15 |
| Olanzapine | Olanzapine | 28 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 28 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 28 | suppressed |
| Risperidone | Risperidone | 28 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 28 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 27 | 11 |
| Prolia | Denosumab | 27 | 14 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 26 | suppressed |
| Methotrexate | Methotrexate Sodium | 26 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 26 | suppressed |
| Topiramate | Topiramate | 25 | suppressed |
| Gemtesa | Vibegron | 24 | suppressed |
| Methylprednisolone | Methylprednisolone | 24 | 23 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 24 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 24 | suppressed |
| Bicalutamide | Bicalutamide | 23 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 22 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 22 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Movantik | Naloxegol Oxalate | 22 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 22 | suppressed |
| Phenobarbital | Phenobarbital | 22 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 21 | suppressed |
| Novolog | Insulin Aspart | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 20 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 20 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 20 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 20 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 19 | suppressed |
| Torsemide | Torsemide | 19 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 18 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 18 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 18 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 18 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Humalog | Insulin Lispro | 16 | suppressed |
| Indapamide | Indapamide | 16 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 15 | suppressed |
| Creon | Lipase/Protease/Amylase | 15 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 15 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 15 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 14 | suppressed |
| Bromocriptine Mesylate | Bromocriptine Mesylate | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Lubiprostone | Lubiprostone | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Armodafinil | Armodafinil | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Livalo | Pitavastatin Calcium | 12 | suppressed |
| Trulance | Plecanatide | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 11 | 11 |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 11 | suppressed |
| Methylphenidate Hcl Er (Cd) | Methylphenidate Hcl | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $919.08 · 36 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, CAPLYTA, Dexcom G6 Transmitter, EVENITY, FARXIGA, Fluad, Flucelvax, GVOKE HYPOPEN, OTEZLA, Ozempic, PROLIA, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, VOQUEZNA, VRAYLAR, ZEPBOUND | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error